No abstract

No abstract

Use of sustained-release bupropion in combination with supportive group therapy may help patients with schizophrenia decrease their cigarette consumption.

Purpose/Background Negative symptoms and cognitive impairments tend to co-occur in people with schizophrenia. If their association with each other is due, in part, to shared pathophysiology, then this suggests that a single drug could potentially be effective for both domains. The current study was designed to examine this hypothesis. Methods/Procedures Fifty-eight participants with either DSM-IV-TR schizophrenia or schizoaffective disorder entered into a 6-week double-blind, placebo-controlled, double-dummy, randomized clinical trial of intranasal oxytocin and galantamine. Seventeen participants were randomized to intranasal oxytocin, 20 were randomized to galantamine and 21 were randomized to placebo. The Scale for the Assessment of Negative Symptoms total score was used to assess change in negative symptoms (the primary outcome measure for oxytocin). The MATRICS Consensus Cognitive Battery composite score was used to assess cognition (the primary outcome measure for galantamine). Findings/Results There were no significant group differences for negative symptoms (oxytocin versus placebo: F=0.19, df=2, 47.4, p=0.83; galantamine versus placebo: F=0.41, df=2, 52.5, p=0.67). There were no significant group differences for cognitive impairments (galantamine versus placebo: t= 0.71, df=40, p=0.48; oxytocin versus placebo: t= 0.50, df=40, p=0.62). There were also no significant group differences for the functional capacity or ancillary symptom measures. Implications/Conclusions The lack of an efficacy signal for either compound precluded our ability to test whether pharmacological treatment pathways for negative symptoms and cognitive impairments overlap or are independent. (clinicaltrials.gov trial number: NCT01012167)

No abstract